#United States #Mountain View #DME #Eluminex Biosciences #EB-105

Eluminex Biosciences Unveils Positive Phase 1b Study Results for Novel Treatment in Diabetic Macular Edema

Eluminex Biosciences Limited has recently announced encouraging outcomes from its Phase 1b study focused on its novel pentavalent trispecific fusion antibody, EB-105, aimed at patients with diabetic macular edema (DME). This groundbreaking therapy represents a significant advancement in the field of protein therapeutics, especially for a condition that threatens vision in many individuals.

The LOTUS study, conducted as an open-label, multicenter trial, assessed the effects of a single ascending dose of EB-105. Patients received intravenous injections at three different dosage levels—low (1.6 mg/eye), mid (4.0 mg/eye), and high (8.0 mg/eye)—and were observed over a three-month period. A total of 13 DME patients from four clinical sites in the United States participated in this rigorous evaluation. The outcomes emerged positive, with no drug-related adverse events reported, affirming the safety and tolerability of the antibody.

Results indicated substantial improvements in visual acuity alongside reductions in central retinal subfield thickness across all dosage groups. As reported, reductions in central retinal thickness ranged from 103 to 429 mm with notable gains in best-corrected visual acuity by 12 to 21 letters across the respective dosages.

Dr. Veeral Sheth, a noted retinal specialist affiliated with the University of Illinois and a key investigator of the trial, emphasized the potential of EB-105. He stated that this antibody could serve as a catalyst for a new generation of treatments for various retinal diseases, extending beyond DME to conditions characterized by IL-6-mediated inflammation such as age-related macular degeneration and retinal vein occlusion.

Follow-up studies are already in the works, with preparations underway for Part 2 of the LOTUS trial, which aims to explore the effects of multiple IVT injections over the course of several months for enhanced treatment possibilities. Dr. Wei Yong Shen, the Chief Scientific Officer of Eluminex, remains optimistic about the results so far, suggesting that further clinical benefits can be attained with continued research into this promising therapeutic approach.

In an age where diabetes-related vision issues are becoming increasingly common, Eluminex Biosciences is positioned at the forefront of innovation, tackling a pressing health concern with breakthroughs that could impact thousands of lives. The enthusiasm surrounding EB-105's initial safety profile and the demonstrated pharmacodynamic benefits underlines the importance of advancing research in effective therapies that address chronic conditions effectively.

The forthcoming presentation of the LOTUS study results at the Clinical Trials at Summit meeting in Las Vegas is highly anticipated, where the research team will share their findings with peers in the medical and scientific community. As the world looks towards innovative solutions to combat vision loss related to diabetes, Eluminex Biosciences continues to pave the way with their commitment to advancing therapeutic treatments.

For those interested in further details, the official website of Eluminex Biosciences provides additional insights into their ongoing projects and research initiatives related to EB-105 and other innovative therapeutic solutions.